vs
GENMAB A/S（GMAB）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是SCANSOURCE, INC.的1.2倍（$925.0M vs $766.5M），GENMAB A/S净利率更高（36.3% vs 2.2%，领先34.2%），GENMAB A/S同比增速更快（18.7% vs 2.5%），GENMAB A/S自由现金流更多（$327.0M vs $28.9M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
GMAB vs SCSC — 直观对比
营收规模更大
GMAB
是对方的1.2倍
$766.5M
营收增速更快
GMAB
高出16.2%
2.5%
净利率更高
GMAB
高出34.2%
2.2%
自由现金流更多
GMAB
多$298.1M
$28.9M
损益表 — Q2 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $766.5M |
| 净利润 | $336.0M | $16.5M |
| 毛利率 | 93.8% | 13.4% |
| 营业利润率 | 38.9% | 2.3% |
| 净利率 | 36.3% | 2.2% |
| 营收同比 | 18.7% | 2.5% |
| 净利润同比 | 65.5% | -3.3% |
| 每股收益（稀释后） | $5.42 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABSCSC
| Q4 25 | — | $766.5M | ||
| Q3 25 | — | $739.6M | ||
| Q2 25 | $925.0M | $812.9M | ||
| Q1 25 | — | $704.8M | ||
| Q4 24 | — | $747.5M | ||
| Q3 24 | — | $775.6M | ||
| Q2 24 | $779.0M | $746.1M | ||
| Q1 24 | — | $752.6M |
净利润GMABSCSC
| Q4 25 | — | $16.5M | ||
| Q3 25 | — | $19.9M | ||
| Q2 25 | $336.0M | $20.1M | ||
| Q1 25 | — | $17.4M | ||
| Q4 24 | — | $17.1M | ||
| Q3 24 | — | $17.0M | ||
| Q2 24 | $203.0M | $16.1M | ||
| Q1 24 | — | $12.8M |
毛利率GMABSCSC
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | 93.8% | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | 96.4% | 13.0% | ||
| Q1 24 | — | 12.6% |
营业利润率GMABSCSC
| Q4 25 | — | 2.3% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | 38.9% | 3.3% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | 30.3% | 2.9% | ||
| Q1 24 | — | 2.3% |
净利率GMABSCSC
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | 36.3% | 2.5% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | 26.1% | 2.2% | ||
| Q1 24 | — | 1.7% |
每股收益（稀释后）GMABSCSC
| Q4 25 | — | $0.75 | ||
| Q3 25 | — | $0.89 | ||
| Q2 25 | $5.42 | $0.87 | ||
| Q1 25 | — | $0.74 | ||
| Q4 24 | — | $0.70 | ||
| Q3 24 | — | $0.69 | ||
| Q2 24 | $3.13 | $0.66 | ||
| Q1 24 | — | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $910.9M |
| 总资产 | $6.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABSCSC
| Q4 25 | — | $83.5M | ||
| Q3 25 | — | $124.9M | ||
| Q2 25 | $1.3B | $126.2M | ||
| Q1 25 | — | $146.3M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | — | $145.0M | ||
| Q2 24 | $622.0M | $185.5M | ||
| Q1 24 | — | $159.1M |
股东权益GMABSCSC
| Q4 25 | — | $910.9M | ||
| Q3 25 | — | $914.0M | ||
| Q2 25 | $5.3B | $906.4M | ||
| Q1 25 | — | $901.7M | ||
| Q4 24 | — | $900.7M | ||
| Q3 24 | — | $920.9M | ||
| Q2 24 | $4.4B | $924.3M | ||
| Q1 24 | — | $944.1M |
总资产GMABSCSC
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $6.5B | $1.8B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $5.6B | $1.8B | ||
| Q1 24 | — | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $28.9M |
| 自由现金流率自由现金流/营收 | 35.4% | 3.8% |
| 资本支出强度资本支出/营收 | 2.4% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.04× | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABSCSC
| Q4 25 | — | $30.8M | ||
| Q3 25 | — | $23.2M | ||
| Q2 25 | $349.0M | — | ||
| Q1 25 | — | $66.1M | ||
| Q4 24 | — | $-6.2M | ||
| Q3 24 | — | $44.8M | ||
| Q2 24 | $438.0M | — | ||
| Q1 24 | — | $160.2M |
自由现金流GMABSCSC
| Q4 25 | — | $28.9M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | $327.0M | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $42.5M | ||
| Q2 24 | $430.0M | — | ||
| Q1 24 | — | $157.7M |
自由现金流率GMABSCSC
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | 55.2% | — | ||
| Q1 24 | — | 21.0% |
资本支出强度GMABSCSC
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 2.4% | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 1.0% | 0.2% | ||
| Q1 24 | — | 0.3% |
现金转化率GMABSCSC
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
